Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (CMMB) generates news primarily as a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting the soluble protein CCL24 in fibro-inflammatory diseases. Much of the company’s news flow centers on clinical data, regulatory interactions and scientific presentations related to primary sclerosing cholangitis (PSC), a rare and progressive liver disease with no effective medical therapy other than liver transplantation in advanced cases.
Investors and observers following Chemomab news can expect detailed updates on the Phase 2 SPRING trial of nebokitug in PSC, including results from the double-blind, placebo-controlled portion and the open label extension, where patients received nebokitug for up to 48 weeks. Press releases describe safety and tolerability findings, changes in biomarkers such as ELF score, PRO-C3 and liver stiffness measurements, and analyses in subgroups with moderate or advanced fibrosis. These reports often highlight biomarker patterns that are associated with PSC disease progression and transplant-free survival.
Chemomab’s news also covers regulatory milestones, such as outcomes of End-of-Phase 2 meetings with the FDA, alignment on a single Phase 3 registration trial design using a composite of clinically relevant events, and agreements on Chemistry, Manufacturing and Controls (CMC) and nonclinical toxicology requirements. Additional announcements address Orphan Drug and Fast Track designations for nebokitug, as well as the status of an open U.S. IND for systemic sclerosis.
Another recurring theme in Chemomab’s news releases is its scientific and investor outreach. The company reports oral and poster presentations at major liver and gastroenterology meetings, including Digestive Disease Week, BSG Live, AASLD The Liver Meeting and EASL congresses, where nebokitug data and CCL24-related mechanisms are discussed. Chemomab also announces participation in rare disease summits and global investment conferences, along with corporate updates tied to quarterly financial results, patent awards and capital markets activities such as at-the-market equity offerings or ADS ratio adjustments.
Readers of the CMMB news page on Stock Titan can use this stream of clinical, regulatory and corporate announcements to track Chemomab’s progress with nebokitug in PSC and other fibro-inflammatory indications, as well as to monitor key events that may influence the company’s development plans and regulatory trajectory.
Chemomab Therapeutics (Nasdaq: CMMB) has presented new positive clinical data at EASL 2025 supporting nebokitug's potential as a first-in-class treatment for Primary Sclerosing Cholangitis (PSC) and related fibro-inflammatory diseases.
The Phase 2 SPRING trial analysis revealed that nebokitug treatment resulted in dose-dependent improvements in multiple inflammatory and fibrotic biomarkers. A comprehensive proteomic analysis of 3,000 circulating proteins showed significant changes in proteins related to fibrosis, immune cell recruitment, and inflammation. The treatment led to downregulation of biological processes including cell-cell adhesion, extracellular matrix organization, and pathways involved in leukocyte migration.
Pharmacokinetic analyses demonstrated dose-proportional increases in nebokitug concentration, with steady-state levels achieved after the fourth dose. Linear regression analyses indicated trends between increasing patient exposure to nebokitug and decreasing levels of PSC disease biomarkers, including liver enzyme and transient elastography scores.
Chemomab Therapeutics (Nasdaq: CMMB) has announced upcoming presentations of clinical data for nebokitug (CM-101) in treating primary sclerosing cholangitis (PSC) at three major scientific conferences.
The presentations will take place at:
- DDW25 (May 3-6, 2025, San Diego) featuring an oral presentation by Dr. Paul Pockros on safety, tolerability, and biomarker improvements
- EASL 2025 (May 7-10, 2025, Amsterdam) with two poster presentations by CEO Adi Mor on pharmacokinetics, pharmacodynamics, and proteomic profile changes
- BSG LIVE'25 (June 23-26, 2025, Glasgow) featuring an oral presentation by Prof. Douglas Thorburn on the SPRING Study results
The presentations will focus on CM-101's impact on inflammation, fibrosis, and cholestasis in PSC patients.
Chemomab Therapeutics (Nasdaq: CMMB) has announced key leadership changes in its medical and clinical teams. David M. Weiner, MD, has been appointed as Interim Chief Medical Officer, returning to a role he previously held in 2021-2022. Additionally, Jack Lawler has been promoted to Chief Development Officer.
Dr. Weiner brings over 25 years of experience in therapeutic discovery and clinical development, replacing Matt Frankel, MD. Lawler, who joined Chemomab in 2022, has been credited with leading the successful Phase 2 SPRING trial for nebokitug in primary sclerosing cholangitis (PSC).
The appointments come at a important time following the company's successful completion of the Phase 2 PSC program. Nebokitug has shown potential to become the first FDA-approved drug for PSC with disease-modifying activity. The company is currently planning its next steps following these positive clinical results.
Chemomab Therapeutics (Nasdaq: CMMB) has reported positive results from the Open Label Extension (OLE) portion of its Phase 2 SPRING trial for nebokitug in primary sclerosing cholangitis (PSC) patients. The trial showed continued improvements across key liver biomarkers after 48 weeks of treatment.
Key findings include:
- Over 90% of eligible SPRING trial patients participated in the OLE
- Patients with moderate/advanced disease showed significantly lower clinical events (4.8%) compared to historical controls (25.8%)
- Treatment demonstrated improvements in liver injury, inflammation, and fibrosis markers
- The drug was well-tolerated at both 10 mg/kg and 20 mg/kg doses administered every three weeks
The results support nebokitug's potential to become the first approved drug with disease-modifying activity for PSC, a deadly disorder currently lacking effective treatments. The 20 mg/kg dose showed particularly strong results and will be used in the upcoming Phase 3 trial.
Chemomab Therapeutics (Nasdaq: CMMB) presented new data at CORA 2025 supporting the potential of nebokitug (CM-101) as a treatment for systemic sclerosis (SSc). The presentation, scheduled for March 8, 2025, in Venice, Italy, showcases nebokitug as a first-in-class monoclonal antibody targeting CCL24, a key driver in fibro-inflammatory conditions.
The new study, conducted with Dr. Alexandra Balbir-Gurman, analyzed skin and serum samples from SSc patients and demonstrated CCL24's role in induced fibrosis and SSc pathogenesis. A 2024 peer-reviewed study of over 200 SSc patients showed that higher CCL24 levels correlated with severe SSc forms and predicted pulmonary function deterioration and higher 10-year mortality.
Recent positive results from the Phase 2 SPRING trial in PSC patients demonstrated nebokitug's effectiveness in reducing fibro-inflammatory biomarkers, including ELF score, PRO-C3, IL-6, and TGF-β, which are also indicators of SSc activity.
Chemomab Therapeutics reported successful completion of FDA End-of-Phase 2 Meeting for nebokitug (CM-101) in Primary Sclerosing Cholangitis (PSC). The company achieved alignment with FDA on a streamlined pathway to potential regulatory approval through a single pivotal Phase 3 trial, without requiring liver biopsies or confirmatory studies.
The Phase 2 SPRING trial met its primary endpoint, demonstrating favorable safety profile. Patients with moderate/advanced disease showed improvements across multiple secondary efficacy endpoints. The company selected the 20mg/kg dose for the Phase 3 trial based on observed dose-dependent responses.
Financial highlights for 2024:
- Cash position: $14.3 million as of December 31, 2024
- R&D expenses: $11.3 million for full year (down from $18.4 million in 2023)
- G&A expenses: $3.4 million (decreased from $7.1 million in 2023)
- Net loss: $13.9 million ($0.04 per share)
The company completed a $10 million private placement in July 2024 with participation from OrbiMed, HBM Partners, and Sphera Biotech Master Fund. Current cash runway extends through Q1 2026.
Chemomab Therapeutics (Nasdaq: CMMB) has successfully completed its End-of-Phase 2 Meeting with the FDA, securing alignment on a single Phase 3 registration study design for nebokitug in Primary Sclerosing Cholangitis (PSC). The Phase 3 trial will require approximately 350 PSC patients and focus on time-to-first-event of well-characterized PSC clinical events, without requiring liver biopsies or additional confirmatory studies.
The streamlined approval pathway could potentially make nebokitug the first FDA-approved treatment for PSC. The trial design is supported by published PSC data linking biomarker improvements seen in the Phase 2 SPRING trial with reduced clinical events. The company expects to report topline data from the SPRING trial's open label extension by the end of Q1 and potentially launch the Phase 3 program before year-end.
The company is currently in discussions with potential strategic partners while preparing for the Phase 3 trial, which is estimated to require about two years for participants to experience clinically-meaningful events.
Chemomab Therapeutics (Nasdaq: CMMB) has announced its participation in the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. CEO Dr. Adi Mor and senior management will deliver a corporate presentation at 8:00 am ET, which will be webcast live and available on the company's website for 90 days.
Chemomab is advancing CM-101, a first-in-class monoclonal antibody targeting CCL24, for fibro-inflammatory diseases. The company recently reported positive results from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC). Two key milestones are expected in early 2025: establishing an FDA registrational pathway for CM-101's Phase 3 pivotal trial and reporting data from the SPRING trial open label extension.
The company plans to initiate the PSC Phase 3 trial by year-end. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment. Additionally, their CM-101 program for systemic sclerosis is Phase 2-ready with an open U.S. IND.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory diseases, announces its participation in Oppenheimer's Movers in Rare Disease Summit on December 12, 2024, at the Westin Grand Central in New York City. The invitation-only event will showcase companies with potential near-term stock-moving catalysts through panels, presentations, and one-on-one investor meetings. Chemomab's management will deliver an Elevator Pitch at 2:45-3:30 pm EST and will be available for individual meetings with registered attendees.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
